Method development and validation of candesartan cilexetil in bulk drug by RP-HPLC
DOI:
https://doi.org/10.61096/ijpar.v7.iss4.2018.579-585Keywords:
RP-HPLC, CDC, Method Development, Validation.Abstract
Candesartan Cilexetil (Candesartan) is a medication utilized for the treatment of Hypertension. The main objective of the present work is to determine a simple, precise, accurate RP-HPLC method. In RP-HPLC, the method was developed (Waters Alliance 2690 with PDA detector) at 250nm. The mobile phase used was Methanol: Water (75:25) and Inertsil C18 ODS (4.6×150mm, 5µ) column was used for separation with a flow rate of 1.0 ml/min. The method was validated for System suitability, Specificity, linearity, accuracy, precision, limit of detection, limit of quantification, Robustness. The linearity was observed in a concentration range of 20-70ppm. The %RSD was found to be <2.0% in all cases and all the validation parameters were found to be within the limits. The proposed method was suitable for the quantitative determination of Candesartan Cilexetil in bulk drug.